Improved survival with bevacizumab in advanced cervical cancer
- PMID: 24552320
- PMCID: PMC4010094
- DOI: 10.1056/NEJMoa1309748
Improved survival with bevacizumab in advanced cervical cancer
Erratum in
-
Improved Survival with Bevacizumab in Advanced Cervical Cancer.N Engl J Med. 2017 Aug 17;377(7):702. doi: 10.1056/NEJMx170002. Epub 2017 Jul 26. N Engl J Med. 2017. PMID: 28745937 No abstract available.
Abstract
Background: Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical cancer develops have previously received cisplatin with radiation therapy, which reduces the effectiveness of cisplatin at the time of recurrence. We evaluated the effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer.
Methods: Using a 2-by-2 factorial design, we randomly assigned 452 patients to chemotherapy with or without bevacizumab at a dose of 15 mg per kilogram of body weight. Chemotherapy consisted of cisplatin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 175 mg per square meter or topotecan at a dose of 0.75 mg per square meter on days 1 to 3, plus paclitaxel at a dose of 175 mg per square meter on day 1. Cycles were repeated every 21 days until disease progression, the development of unacceptable toxic effects, or a complete response was documented. The primary end point was overall survival; a reduction of 30% in the hazard ratio for death was considered clinically important.
Results: Groups were well balanced with respect to age, histologic findings, performance status, previous use or nonuse of a radiosensitizing platinum agent, and disease status. Topotecan-paclitaxel was not superior to cisplatin-paclitaxel (hazard ratio for death, 1.20). With the data for the two chemotherapy regimens combined, the addition of bevacizumab to chemotherapy was associated with increased overall survival (17.0 months vs. 13.3 months; hazard ratio for death, 0.71; 98% confidence interval, 0.54 to 0.95; P=0.004 in a one-sided test) and higher response rates (48% vs. 36%, P=0.008). Bevacizumab, as compared with chemotherapy alone, was associated with an increased incidence of hypertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%), and gastrointestinal fistulas of grade 3 or higher (3% vs. 0%).
Conclusions: The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4010094/bin/nihms-572662-f0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4010094/bin/nihms-572662-f0002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4010094/bin/nihms-572662-f0003.gif)
Comment in
-
Targeted therapies: Further delineating bevacizumab's response spectrum.Nat Rev Clin Oncol. 2014 May;11(5):243-4. doi: 10.1038/nrclinonc.2014.61. Epub 2014 Apr 8. Nat Rev Clin Oncol. 2014. PMID: 24710578 No abstract available.
-
Are there alternative ways to quantify the real benefit of novel agents in oncology? - the 'death pace'.Cancer Biol Ther. 2015;16(2):187-8. doi: 10.1080/15384047.2014.1002368. Cancer Biol Ther. 2015. PMID: 25756506 Free PMC article. No abstract available.
Similar articles
-
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).Lancet Oncol. 2015 Mar;16(3):301-11. doi: 10.1016/S1470-2045(15)70004-5. Epub 2015 Jan 29. Lancet Oncol. 2015. PMID: 25638326 Free PMC article. Clinical Trial.
-
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27. Lancet. 2017. PMID: 28756902 Free PMC article. Clinical Trial.
-
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).Int J Gynecol Cancer. 2020 Jan;30(1):139-143. doi: 10.1136/ijgc-2019-000880. Epub 2019 Oct 23. Int J Gynecol Cancer. 2020. PMID: 31645423 Clinical Trial.
-
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.Int J Gynecol Cancer. 2017 Jul;27(6):1237-1246. doi: 10.1097/IGC.0000000000001000. Int J Gynecol Cancer. 2017. PMID: 28448304 Free PMC article. Review.
-
Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.Expert Opin Pharmacother. 2015 Apr;16(5):675-83. doi: 10.1517/14656566.2015.1010511. Epub 2015 Feb 3. Expert Opin Pharmacother. 2015. PMID: 25643984 Review.
Cited by
-
Deep learning to assess microsatellite instability directly from histopathological whole slide images in endometrial cancer.NPJ Digit Med. 2024 May 29;7(1):143. doi: 10.1038/s41746-024-01131-7. NPJ Digit Med. 2024. PMID: 38811811 Free PMC article.
-
Peroxiredoxin 2 as a potential prognostic biomarker associated with angiogenesis in cervical squamous cell cancer.Oncol Lett. 2024 May 16;28(1):328. doi: 10.3892/ol.2024.14461. eCollection 2024 Jul. Oncol Lett. 2024. PMID: 38807674 Free PMC article.
-
Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer.BMC Cancer. 2024 May 15;24(1):589. doi: 10.1186/s12885-024-12358-8. BMC Cancer. 2024. PMID: 38745137 Free PMC article.
-
Serum Proteomic Signatures in Cervical Cancer: Current Status and Future Directions.Cancers (Basel). 2024 Apr 24;16(9):1629. doi: 10.3390/cancers16091629. Cancers (Basel). 2024. PMID: 38730581 Free PMC article. Review.
-
The efficacy of immune checkpoint inhibitors on low PD-L1 cervical cancer: A meta-analysis.Health Sci Rep. 2024 May 2;7(5):e2069. doi: 10.1002/hsr2.2069. eCollection 2024 May. Health Sci Rep. 2024. PMID: 38706804 Free PMC article.
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
-
- Tewari KS, Monk BJ. Invasive cervical cancer. In: DiSaia PJ, Creasman WT, editors. Clinical gynecologic oncology. 8th ed. Mosby; Philadelphia: 2012.
-
- Monk BJ, Tewari KS, Koh WJ. Multi-modality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952–65. - PubMed
-
- Tewari KS. Expert panel: patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Clin Ovarian Cancer. 2011;4:90–3.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical